Metastatic basal cell carcinoma to the bone: a case of bone metastasis in uncommon sites

Olga Nigro; Claudio Chini; Ilaria Gioia Angiola Marcon; Annamaria De Giorgi; Linda Bascialla; Elisa Gallerani; Alice Giaquinto; Diego De Palma; Maurizio Lombardo

doi:10.4081/dr.2022.9267

Authors

Olga Nigro
olga.nigro@outlook.it
Medical Oncology, ASST-Settelaghi, Ospedale di Circolo Fondazione Macchi, Varese, Italy. https://orcid.org/0000-0002-1030-2809
Claudio Chini Medical Oncology, ASST-Settelaghi, Ospedale di Circolo Fondazione Macchi, Varese, Italy.
Ilaria Gioia Angiola Marcon Medical Oncology, ASST-Settelaghi, Ospedale di Circolo Fondazione Macchi, Varese, Italy.
Annamaria De Giorgi Medical Oncology, ASST-Settelaghi, Ospedale di Circolo Fondazione Macchi, Varese, Italy.
Linda Bascialla Medical Oncology, ASST-Settelaghi, Ospedale di Circolo Fondazione Macchi, Varese, Italy.
Elisa Gallerani Medical Oncology, ASST-Settelaghi, Ospedale di Circolo Fondazione Macchi, Varese, Italy.
Alice Giaquinto Medical Oncology, ASST-Settelaghi, Ospedale di Circolo Fondazione Macchi, Varese, Italy.
Diego De Palma Nuclear Medicine, ASST-Settelaghi, Ospedale di Circolo Fondazione Macchi, Varese, Italy.
Maurizio Lombardo Dermatology Department, ASST-Settelaghi, Ospedale di Circolo Fondazione Macchi, Varese, Italy.

Basal cell carcinoma (BCC) is the most common malignant tumor of the skin. Despite the indolent nature, metastatic BCC can occur, albeit rarely. Metastasis to the bone is very rare. From its approval, mBCC patients are treated with vismodegib, a selective hedgehog pathway inhibitor. Unfortunately, in recent period, it was demonstrated an emergence of drug resistance, due to Smoothened (SMO) mutation. To date, several groups are studying the effectiveness of immunotherapy in BCC. Clinical trials with immune checkpoint inhibitors are ongoing. We report the rare case of a man with multiple bony metastasis, with a resistance to vismodegib, and we evaluated all manuscripts in literature reporting bone metastasis. Moreover, we review all the manuscripts in literature reporting bone metastasis, and we summarize the main therapeutic strategies, and the further perspectives.

Gailani MR, Leffell DJ, Ziegler A, et al. Relationship between sunlight exposure and a key genetic alteration in basal cell carcinoma. J Natl Cancer Inst 1996;8:349–54.

Bonilla X, Parmentier L, King B et al. Genomic analysis identifies new drivers and progression pathways in skin basal cell carcinoma. Nat Genet 2016;48:398-406.

Rubin AI, Chen EH, Ratner D. Basal-cell carcinoma. N Engl J Med 2005;353:2262–9.

Telfer NR, Colver GB, Morton CA. British Association of Dermatologists. Guidelines for the management of basal cell carcinoma. Br J Dermatol 2008;159:35–48.

McCuskerM, Basset-Seguin N, Dummer R et al. Metastatic basal cell carcinoma: prognosis dependent on anatomic site and spread of disease. Eur J Cancer 2014;50:774–83.

von Domarus H, Stevens PJ. Metastatic basal cell carcinoma. Report of five cases and review of 170 cases in the literature. J Am Acad Dermatol 1984;10:1043–60.

Snow SN, Sahl WJ, Lo J et al. Metastatic basal cell carcinoma: report of five cases. Cancer 1994;73:328-35.

Barksdale SK, O’Connor N, Barnhill R. Prognostic factors for cutaneous squamous cell and basal cell carcinoma. Determinants of risk of recurrence, metastasis, and development of subsequent skin cancers. Surg Oncol Clin N Am 1997;6:625–38.

von Domarus H, Stevens PJ. Metastatic basal cell carcinoma. Report of five cases and review of 170 cases in the literature. J Am Acad Dermatol 1984;10:1043–60.

Axelson M, Liu K, Jiang X et al. U.S. Food and Drug Administration approval: vismodegib for recurrent, locally advanced, or metastatic basal cell carcinoma. Clin Cancer Res 2013;19:2289-93.

Sofen H, Gross KG, Goldberg LH et al. A phase II, multicenter, open-label, 3-cohort trial evaluating the efficacy and safety of vismodegib in operable basal cell carcinoma. J Am Acad Dermatol 2015;73:99-105.

US Department of Veterans Affairs (VA) Pharmacy Benefits Management Services; Medical Advisory Panel; VIAN Pharmacist Executive. Vismodegib (Erivedge) National Drug Monograph. Washington, DC: US VA; 2013. https://www.pbm.va.gov/clinicalguidance/drugmonographs/vismodegib_drug_monograph.docx

Erdem GU, Sendur MA, Ozdemir NY et al. A comprehensive review of the role of Hedgehog pathway and vismodegib in the management of basal cell carcinoma. Curr Med Res Opin 2015;31:743-56.

Sekulic A, Von Hoff D. Hedgehog pathway inhibition. Cell 2016;164:831.

Bonilla X, Parmentier L, King B, et al. Genomic analysis identifies new drivers and progression pathways in skin basal cell carcinoma. Nat Genet 2016;48:398-406.

Grund-Gröschke S, Stockmaier G, Aberger F. Hedgehog/GLI signaling in tumor immunity - new therapeutic opportunities and clinical implications. Cell Commun Signal 2019;17:172.

Lipson EJ, Lilo MT, Ogurtsova A, et al. Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade. J Immunother Cancer 2016;21;5:23.

Fischer S, Ali OH, Jochum W, et al. Anti-PD-1 Therapy Leads to Near-Complete Remission in a Patient with Metastatic Basal Cell Carcinoma. Oncol Res Treat 2018;41:391–4.

Moreira A, Kirchberger MC, Toussaint F, et al. Effective anti-programmed death-1 therapy in a SUFU-mutated patient with Gorlin-Goltz syndrome. Br J Dermatol 2018;179:747–9.

Chang ALS, Tran DC, Cannon JGD, et al. Pembrolizumab for advanced basal cell carcinoma: An investigator-initiated, proof-of-concept study. J Am Acad Dermatol 2019;80:564–6.

Annamaria De Giorgi, Medical Oncology, ASST-Settelaghi, Ospedale di Circolo Fondazione Macchi, Varese

Nigro, O., Chini, C., Marcon, I. G. A., De Giorgi, A., Bascialla, L., Gallerani, E., Giaquinto, A., De Palma, D., & Lombardo, M. (2022). Metastatic basal cell carcinoma to the bone: a case of bone metastasis in uncommon sites. Dermatology Reports, 14(3). https://doi.org/10.4081/dr.2022.9267